FDA Review of Novavax’s COVID-19 Vaccine—Regulatory Integrity and Deviations From Standard Practice

This Viewpoint notes that the review and communication processes for the Novavax COVID-19 vaccine deviated from standard practice and raises concerns if this is the “new normal” for the FDA.

Authors

Institutions

Publication Details

Journal
JAMA
Published
2025-06-09
DOI
https://doi.org/10.1001/jama.2025.9898
Citations
5
Primary Topic
Vaccine Coverage and Hesitancy
Type
article
Field-Weighted Citation Impact
10.84
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

FDA Review of Novavax’s COVID-19 Vaccine—Regulatory Integrity and Deviations From Standard Practice

Patricia J. Zettler, Peter Lurie, Sarah Despres, Stephen Cha
5 citations
JAMA
Vaccine Coverage and Hesitancy
10.84
article

FDA Review of Novavax’s COVID-19 Vaccine—Regulatory Integrity and Deviations From Standard Practice

Patricia J. Zettler, Peter Lurie, Sarah Despres, Stephen Cha
article en
5 citations

Abstract

This Viewpoint notes that the review and communication processes for the Novavax COVID-19 vaccine deviated from standard practice and raises concerns if this is the “new normal” for the FDA.

JAMAVol. 334(6)
Center for Science in the Public Interest (United States) (US)
Openalex Percentile: Top 2%
Vaccine Coverage and Hesitancy
10.84
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

FDA Review of Novavax’s COVID-19 Vaccine—Regulatory Integrity and Deviations From Standard Practice — Patricia J. Zettler, Peter Lurie, et al. · JAMA (2025) | TGRS Research Map | TGRS